Over 90 Total Lots Up For Auction at One Location - WA 04/08

MaxQ AI's Accipio Software integrated as part of GE Healthcare's Smart Subscription platform

Press releases may be edited for formatting or style | November 28, 2018

Accipio Ix, which has received both FDA clearance and CE Mark certification, leverages artificial intelligence technology to automatically analyze non-contrast head CT images. The AI-powered Accipio Ix, part of MaxQ's unique Accipio INSIGHT™ platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with a brain bleed for the treating physician. It provides a capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and in the future, cloud-capable.

MaxQ is demonstrating Accipio Ix – along with the full suite of Accipio platform solutions – during this week's Radiological Society of North America (RSNA) 2018 Annual Meeting in Chicago (Booth #6161 in the North Hall).


About MaxQ AI, Ltd.
MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide 'smarter care' with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, our team of deep learning and machine vision experts develop clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis. Working with world-class clinical and industry partners, we are raising the level of acute care in hospitals around the world to improve patient outcomes and lower costs. To learn more, please visit www.maxq.ai or follow us on Twitter and LinkedIn.

Back to HCB News

You Must Be Logged In To Post A Comment